NO20075603L - Nye 5-substituerte 7-amino[1,3]tiazol[4,5-d]pyrimidinderivater - Google Patents
Nye 5-substituerte 7-amino[1,3]tiazol[4,5-d]pyrimidinderivaterInfo
- Publication number
- NO20075603L NO20075603L NO20075603A NO20075603A NO20075603L NO 20075603 L NO20075603 L NO 20075603L NO 20075603 A NO20075603 A NO 20075603A NO 20075603 A NO20075603 A NO 20075603A NO 20075603 L NO20075603 L NO 20075603L
- Authority
- NO
- Norway
- Prior art keywords
- thiazole
- amino
- substituted
- disease
- pyrimidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0500767 | 2005-04-06 | ||
PCT/SE2006/000399 WO2006107258A1 (en) | 2005-04-06 | 2006-04-03 | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20075603L true NO20075603L (no) | 2008-01-04 |
Family
ID=37073739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20075603A NO20075603L (no) | 2005-04-06 | 2007-11-05 | Nye 5-substituerte 7-amino[1,3]tiazol[4,5-d]pyrimidinderivater |
Country Status (31)
Country | Link |
---|---|
US (2) | US7947693B2 (pt) |
EP (1) | EP1869056B1 (pt) |
JP (1) | JP5165553B2 (pt) |
KR (1) | KR101335055B1 (pt) |
CN (1) | CN101193897B (pt) |
AR (1) | AR055890A1 (pt) |
AT (1) | ATE487727T1 (pt) |
AU (1) | AU2006231836B2 (pt) |
BR (1) | BRPI0609738A2 (pt) |
CA (1) | CA2604017C (pt) |
CY (1) | CY1111316T1 (pt) |
DE (1) | DE602006018124D1 (pt) |
DK (1) | DK1869056T3 (pt) |
ES (1) | ES2354450T3 (pt) |
HK (1) | HK1118556A1 (pt) |
HR (1) | HRP20110047T1 (pt) |
IL (1) | IL185912A0 (pt) |
MX (1) | MX2007012060A (pt) |
NO (1) | NO20075603L (pt) |
NZ (1) | NZ561460A (pt) |
PL (1) | PL1869056T3 (pt) |
PT (1) | PT1869056E (pt) |
RS (1) | RS51581B (pt) |
RU (1) | RU2419623C2 (pt) |
SA (1) | SA06270072B1 (pt) |
SI (1) | SI1869056T1 (pt) |
TW (1) | TW200714605A (pt) |
UA (1) | UA90707C2 (pt) |
UY (1) | UY29454A1 (pt) |
WO (1) | WO2006107258A1 (pt) |
ZA (1) | ZA200708187B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2641815T3 (es) | 2004-10-29 | 2017-11-14 | Eisai R&D Management Co., Ltd. | Tratamiento para enfermedades inflamatorias |
AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
TW200820973A (en) | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
JP2010504963A (ja) * | 2006-09-29 | 2010-02-18 | アストラゼネカ・アクチエボラーグ | 新規な5,7−二置換された[1,3]チアゾロ[4,5−d]ピリミジン−2(3h)−アミン誘導体及び治療におけるその使用 |
GEP20135913B (en) | 2008-03-07 | 2013-08-26 | Acraf | 1-benzyl-3-hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1 and cx3cr1 expression |
WO2009109616A2 (en) | 2008-03-07 | 2009-09-11 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzil-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
KR101599867B1 (ko) | 2008-03-07 | 2016-03-04 | 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 | 신규한 1-벤질-3-하이드록시메틸인다졸 유도체들 및 mcp-1, cx3cr1 및 p40의 발현을 기초로 한 질환들의 치료에서 이의 용도 |
US9040538B2 (en) | 2009-05-21 | 2015-05-26 | Universite Laval | Pyrimidines as novel therapeutic agents |
JO3437B1 (ar) | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
WO2012078633A2 (en) | 2010-12-07 | 2012-06-14 | Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene | Methods of inhibiting metastasis from cancer |
TWI543975B (zh) | 2011-09-13 | 2016-08-01 | Eisai R&D Man Co Ltd | Pyrrolidin-3-yl acetic acid derivatives |
US8476301B2 (en) | 2011-09-13 | 2013-07-02 | Eisai R&D Management Co., Ltd. | Pyrrolidin-3-ylacetic acid derivative |
US9550732B2 (en) | 2013-03-12 | 2017-01-24 | Eisai R&D Management Co., Ltd. | Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof |
RU2016110852A (ru) * | 2013-09-27 | 2017-10-30 | Нимбус Айрис, Инк. | Ингибиторы irak и их применения |
US20180222922A1 (en) * | 2015-06-08 | 2018-08-09 | The Johns Hopkins University | Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1) |
US11267817B2 (en) | 2017-05-02 | 2022-03-08 | Drexel University | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists |
GB201807898D0 (en) * | 2018-05-15 | 2018-06-27 | Kancera Ab | New processes and products with increased chiral purity |
GB201811169D0 (en) | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
GB202006849D0 (en) | 2020-05-08 | 2020-06-24 | Kancera Ab | New use |
WO2024083933A1 (en) | 2022-10-19 | 2024-04-25 | Astrazeneca Ab | 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3cr1 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE543978A (pt) | 1955-01-03 | |||
US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
US4643987A (en) | 1985-08-14 | 1987-02-17 | Eli Lilly And Company | Modified glycopeptides |
US4639433A (en) | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
NZ236393A (en) | 1989-12-13 | 1992-05-26 | Lilly Co Eli | N-alkylated glycopeptide derivatives prepared from antibiotics a82846 series and pa-42867-a; pharmaceutical compositions |
US5202328A (en) | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
AU3213699A (en) | 1998-04-03 | 1999-10-25 | Du Pont Pharmaceuticals Company | Thiazolo(4,5-d)pyrimidines and pyridines as corticotropin releasing factor (CRF)antagonists |
JP4307723B2 (ja) | 1998-05-01 | 2009-08-05 | イーライ リリー アンド カンパニー | N1−修飾グリコペプチド |
SE9802729D0 (sv) | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
EP1257555B1 (en) * | 2000-02-11 | 2003-12-03 | AstraZeneca AB | Pyrimidine compounds and their use as modulators of chemokine receptor activity |
GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
SE0004110L (sv) | 2000-11-10 | 2002-05-11 | Forsheda Ab | Tätningsring |
SE0101082D0 (sv) * | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
GB0221829D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
US8110209B2 (en) * | 2002-12-20 | 2012-02-07 | Xeris Pharmaceuticals Inc. | Intracutaneous injection |
JP2007507494A (ja) * | 2003-10-07 | 2007-03-29 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体アンタゴニストとりわけCX3CR1として有用な新規な2−置換4−アミノ−チアゾロ[4,5−d]ピリミジン |
JP2008524186A (ja) * | 2004-12-17 | 2008-07-10 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体活性の調節のためのチアゾロピラミジン化合物 |
AR053347A1 (es) * | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
-
2006
- 2006-03-04 UA UAA200710491A patent/UA90707C2/ru unknown
- 2006-03-27 AR ARP060101169A patent/AR055890A1/es not_active Application Discontinuation
- 2006-03-28 TW TW095110726A patent/TW200714605A/zh unknown
- 2006-03-29 SA SA06270072A patent/SA06270072B1/ar unknown
- 2006-04-03 CN CN2006800200726A patent/CN101193897B/zh active Active
- 2006-04-03 WO PCT/SE2006/000399 patent/WO2006107258A1/en active Application Filing
- 2006-04-03 EP EP06717078A patent/EP1869056B1/en active Active
- 2006-04-03 US US11/910,780 patent/US7947693B2/en active Active
- 2006-04-03 BR BRPI0609738-3A patent/BRPI0609738A2/pt not_active IP Right Cessation
- 2006-04-03 DE DE602006018124T patent/DE602006018124D1/de active Active
- 2006-04-03 AT AT06717078T patent/ATE487727T1/de active
- 2006-04-03 RU RU2007140551/04A patent/RU2419623C2/ru not_active IP Right Cessation
- 2006-04-03 DK DK06717078.7T patent/DK1869056T3/da active
- 2006-04-03 JP JP2008505262A patent/JP5165553B2/ja active Active
- 2006-04-03 SI SI200630886T patent/SI1869056T1/sl unknown
- 2006-04-03 PT PT06717078T patent/PT1869056E/pt unknown
- 2006-04-03 CA CA2604017A patent/CA2604017C/en not_active Expired - Fee Related
- 2006-04-03 RS RS20110006A patent/RS51581B/en unknown
- 2006-04-03 KR KR1020077022813A patent/KR101335055B1/ko not_active IP Right Cessation
- 2006-04-03 NZ NZ561460A patent/NZ561460A/en not_active IP Right Cessation
- 2006-04-03 PL PL06717078T patent/PL1869056T3/pl unknown
- 2006-04-03 AU AU2006231836A patent/AU2006231836B2/en not_active Ceased
- 2006-04-03 MX MX2007012060A patent/MX2007012060A/es active IP Right Grant
- 2006-04-03 ES ES06717078T patent/ES2354450T3/es active Active
- 2006-04-04 UY UY29454A patent/UY29454A1/es not_active Application Discontinuation
-
2007
- 2007-09-11 IL IL185912A patent/IL185912A0/en unknown
- 2007-09-25 ZA ZA200708187A patent/ZA200708187B/xx unknown
- 2007-11-05 NO NO20075603A patent/NO20075603L/no not_active Application Discontinuation
-
2008
- 2008-11-14 HK HK08112536.8A patent/HK1118556A1/xx not_active IP Right Cessation
-
2010
- 2010-12-28 US US12/979,720 patent/US9440992B2/en active Active
-
2011
- 2011-01-13 CY CY20111100040T patent/CY1111316T1/el unknown
- 2011-01-21 HR HR20110047T patent/HRP20110047T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20075603L (no) | Nye 5-substituerte 7-amino[1,3]tiazol[4,5-d]pyrimidinderivater | |
NO20075610L (no) | Nye 5,7-disubstituerte [1,3]tiazol[4,5-d]pyrlmldin-2(3H)-onderivater | |
TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
ATE530519T1 (de) | Cyclobutylaminderivate | |
WO2006067614A3 (en) | Heteroaromatic derivatives useful as anticancer agents | |
NO20071703L (no) | Kinazolinderivater | |
SG162807A1 (en) | Azaindazole compounds and methods of use | |
TW200637863A (en) | Organic compounds | |
MY147390A (en) | Substituted isoindoles as bace inhibitors and their use | |
NO20091577L (no) | Nye 5,7-disubstituerte (1,3)tiazolo[4,5-D]pyrimidin-2(3H)-aminderivater og deres anvendelse i terapi | |
NO20092689L (no) | Quinuclidinolderivater som muskarin reseptorantagonister | |
NO20065327L (no) | Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid. | |
NO20075059L (no) | Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase | |
TW200630366A (en) | Organic compounds | |
NO20080445L (no) | Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer | |
DK1926729T3 (da) | Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander | |
ATE531692T1 (de) | Als antagonisten am muskarinrezeptor geeignete guanidinhaltige verbindungen | |
IL186777A0 (en) | (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor | |
NO20082054L (no) | Nye 2-fenylimidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase for behandling av demens og neurodegenerative forstyrrelser | |
WO2007110340A3 (en) | Pyrimidine, quinazoline, pteridine and triazine derivatives | |
NO20081082L (no) | Nye piperidinderivater som kjemokinreseptorformulatorer som er nyttige for behandling av respiratoriske sykdommer | |
WO2008104473A3 (en) | Pyrazolopyriidine derivatives and their use as kinase inhibitors | |
NO20065551L (no) | Anvendelse av opoid reseptor antagonistforbindelser for forhindring og/eller behandling av sykdommer assosiert med malet calcineurin | |
NO20091579L (no) | Nye 5,7-disubstituerte [1,3]tiazolo[4,5-d]pyrimidin-2(3H)-onderivater og deres anvendelse i terapi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |